Rare ICU Toxidromes: Contemporary Management of Bupropion, Synthetic Cannabinoids, and Paraquat Poisoning

Dr Neeraj Manikath , claude.ai

Abstract

Background: Critical care physicians increasingly encounter rare toxidromes that pose unique diagnostic and therapeutic challenges. This review examines three distinct poisoning syndromes: bupropion toxicity, synthetic cannabinoid intoxication, and paraquat poisoning.

Objective: To provide evidence-based management strategies, clinical pearls, and practical approaches for intensivists managing these uncommon but potentially lethal toxidromes.

Methods: Comprehensive literature review of peer-reviewed publications, case series, and expert consensus statements from 2010-2024.

Results: Each toxidrome presents with distinct pathophysiology, clinical presentations, and management requirements. Early recognition and targeted interventions significantly impact outcomes.

Conclusions: Mastery of these rare toxidromes requires understanding unique mechanisms, rapid diagnostic approaches, and specialized treatment protocols to optimize patient outcomes in the ICU setting.

Keywords: Toxicology, Critical Care, Bupropion, Synthetic Cannabinoids, Paraquat, Emergency Medicine

Introduction

The modern intensive care unit (ICU) serves as the final defense against life-threatening poisonings. While common toxidromes like acetaminophen or salicylate poisoning are well-recognized, rare toxidromes present unique challenges that can perplex even experienced intensivists. This review focuses on three increasingly encountered but poorly understood poisoning syndromes: bupropion toxicity, synthetic cannabinoid intoxication, and paraquat poisoning.

These toxidromes share several concerning characteristics: delayed presentations, multiorgan involvement, limited antidotal therapy, and high morbidity-mortality rates when mismanaged. Understanding their unique pathophysiology, clinical presentations, and evidence-based management strategies is crucial for optimal patient outcomes.

Bupropion Toxicity

Pathophysiology

Bupropion, a norepinephrine-dopamine reuptake inhibitor antidepressant, demonstrates dose-dependent toxicity through multiple mechanisms. At therapeutic doses, it selectively inhibits presynaptic reuptake of norepinephrine and dopamine while minimally affecting serotonin transport¹. However, in overdose, bupropion exhibits:

Sodium channel blockade: Leading to QRS widening and cardiac conduction abnormalities
GABA antagonism: Precipitating seizures through reduced inhibitory neurotransmission
Calcium channel interference: Contributing to cardiovascular collapse
Enhanced catecholamine activity: Causing hypertensive crises and arrhythmias

Clinical Presentation

🔍 Clinical Pearl: The "bupropion triad" consists of seizures, altered mental status, and cardiac conduction abnormalities - but only 60% of patients present with all three features².

Early Phase (0-4 hours)

Agitation, anxiety, tremor
Mild hypertension and tachycardia
Nausea and vomiting

Intermediate Phase (4-12 hours)

Progressive altered mental status
QRS widening (>100ms indicates severe toxicity)
First seizures typically occur within 8 hours

Late Phase (>12 hours)

Status epilepticus
Cardiovascular collapse
Multiorgan failure

⚠️ Oyster Alert: Extended-release formulations can cause delayed toxicity up to 24 hours post-ingestion, requiring prolonged observation even in initially asymptomatic patients³.

Diagnostic Approach

Laboratory Studies:

Basic metabolic panel (assess anion gap metabolic acidosis)
Arterial blood gas
Lactate levels
Cardiac biomarkers if chest pain or ECG changes
Serum bupropion levels (if available, though correlation with toxicity is poor)

Imaging:

ECG every 2-4 hours for first 24 hours
Chest X-ray if aspiration suspected
Head CT if prolonged altered mental status

🔧 ICU Hack: QRS duration >100ms predicts seizure risk better than serum bupropion levels. Monitor ECGs continuously rather than relying on intermittent measurements⁴.

Management Strategies

Immediate Interventions

Airway Management
- Early intubation for altered mental status or seizures
- Avoid succinylcholine if hyperkalemia suspected
Seizure Control
- First-line: Benzodiazepines (lorazepam 2-4mg IV or diazepam 10-20mg IV)
- Second-line: Propofol or barbiturates
- Avoid phenytoin (may worsen cardiac toxicity)
Cardiac Toxicity
- Sodium bicarbonate 1-2 mEq/kg IV for QRS >100ms
- Target arterial pH 7.45-7.55
- Hypertonic saline (3%) 100-200mL if bicarbonate unavailable

Advanced Interventions

Refractory seizures: Consider burst-suppression with pentobarbital or propofol
Cardiovascular collapse: Early ECMO consideration in appropriate candidates
Hyperthermia: Aggressive cooling measures

💡 Management Pearl: Lipid emulsion therapy (20% intralipid 1.5mL/kg bolus, then 0.25mL/kg/min) may be beneficial in severe cases, though evidence remains limited⁵.

Synthetic Cannabinoid Intoxication

Pathophysiology

Synthetic cannabinoids (SC) represent a diverse group of compounds that act as full agonists at cannabinoid CB1 and CB2 receptors, unlike THC which acts as a partial agonist⁶. This full agonism explains their increased potency and toxicity profile.

Key Mechanisms:

CB1 receptor overstimulation: CNS depression, psychosis
CB2 receptor activation: Immunosuppression, anti-inflammatory effects
Off-target effects: Serotonin, GABA, and NMDA receptor interactions
Adulterants: Often contaminated with brodifacoum, fentanyl, or other substances

Clinical Presentation

🔍 Clinical Pearl: Unlike natural cannabis, synthetic cannabinoids can cause severe CNS depression, seizures, and cardiovascular collapse - making the "safe marijuana" assumption dangerous⁷.

Acute Intoxication Syndrome

CNS: Altered mental status, agitation, psychosis, seizures, coma
Cardiovascular: Tachycardia, hypertension, chest pain, MI
Pulmonary: Tachypnea, acute lung injury
Renal: Acute kidney injury (particularly with certain compounds)
Metabolic: Severe hypokalemia, metabolic acidosis

Unique Presentations

"Zombie-like" behavior: Catatonic appearance with periods of agitation
Coagulopathy: Particularly with brodifacoum-adulterated products
Rhabdomyolysis: From prolonged immobility or hyperthermia

Diagnostic Challenges

⚠️ Oyster Alert: Standard urine drug screens do not detect synthetic cannabinoids. Specialized testing requires gas chromatography-mass spectrometry and is rarely available acutely⁸.

Clinical Diagnosis

History of "spice," "K2," or herbal smoking product use
Negative urine cannabinoid screen despite recent "marijuana" use
Severe symptoms inconsistent with natural cannabis

Laboratory Studies

Comprehensive metabolic panel (watch for severe hypokalemia)
PT/PTT/INR (assess for coagulopathy)
Creatine kinase and myoglobin
Troponin if chest pain
Arterial blood gas

🔧 ICU Hack: Severe hypokalemia (K+ <2.5 mEq/L) in a young patient with altered mental status should raise suspicion for synthetic cannabinoid use, even without smoking history⁹.

Management Approach

Supportive Care Framework

CNS Management
- Benzodiazepines for agitation and seizures
- Haloperidol 5-10mg IM for severe psychosis
- Avoid physical restraints when possible
Cardiovascular Support
- Continuous cardiac monitoring
- Beta-blockers for hypertension and tachycardia
- Standard ACS protocols if ischemia suspected
Electrolyte Management
- Aggressive potassium replacement (often requires >200 mEq)
- Monitor for rebound hyperkalemia
- Magnesium supplementation

Special Considerations

Brodifacoum coagulopathy: High-dose vitamin K1 (50-100mg daily) for weeks to months
Acute kidney injury: Early nephrology consultation
Hyperthermia: Active cooling measures

💡 Management Pearl: Consider synthetic cannabinoid toxicity in any young patient presenting with the triad of altered mental status, severe hypokalemia, and negative standard drug screen¹⁰.

Paraquat Poisoning

Pathophysiology

Paraquat (1,1'-dimethyl-4,4'-bipyridinium dichloride) is a highly toxic herbicide that causes multi-organ failure through oxidative stress mechanisms¹¹. Its toxicity stems from:

Redox Cycling:

Paraquat accepts electrons from NADPH
Forms superoxide radicals in the presence of oxygen
Continuous cycle depletes cellular reducing equivalents
Overwhelming oxidative stress leads to cellular death

Organ-Specific Toxicity:

Lungs: Highest concentration due to polyamine uptake system
Kidneys: Primary elimination route, causing acute tubular necrosis
Liver: Hepatocellular necrosis and fibrosis
Heart: Myocardial damage and arrhythmias

Clinical Presentation

🔍 Clinical Pearl: The "index of severity" (amount ingested in mg/kg) predicts outcome better than serum levels. >6 mg/kg is usually fatal¹².

Phase I (0-24 hours): Gastrointestinal

Severe oral and esophageal burns
Nausea, vomiting, abdominal pain
Hematemesis and melena
Pharyngeal edema (may require emergent airway management)

Phase II (1-7 days): Multi-organ Failure

Renal: Oliguria, elevated creatinine, electrolyte disturbances
Hepatic: Elevated transaminases, coagulopathy
Cardiac: Arrhythmias, myocarditis

Phase III (>7 days): Pulmonary Fibrosis

Progressive dyspnea
Bilateral pulmonary infiltrates
Irreversible pulmonary fibrosis
Respiratory failure

⚠️ Oyster Alert: A "latent period" of 2-5 days with minimal symptoms often precedes the onset of severe organ toxicity. Early intervention during this window is critical¹³.

Diagnostic Approach

Laboratory Studies

Immediate: CBC, BUN/Cr, LFTs, PT/PTT, ABG
Serial monitoring: Creatinine, transaminases, PaO2/FiO2 ratio
Paraquat levels: If available (>3 μg/mL at 4 hours predicts poor outcome)

Severity Assessment

Proudfoot Classification:

Mild: <20 mg/kg, survival likely with treatment
Moderate: 20-40 mg/kg, survival possible with aggressive care
Severe: >40 mg/kg, usually fatal despite treatment

🔧 ICU Hack: Calculate the "paraquat-time nomogram" - plot serum level against time since ingestion. Patients above the survival curve have poor prognosis despite maximal therapy¹⁴.

Management Strategies

Immediate Interventions (First 4-6 hours)

Decontamination
- Fuller's earth (bentonite clay) 2g/kg PO if available
- Alternative: Activated charcoal 1g/kg (less effective)
- Avoid gastric lavage due to corrosive effects
Enhanced Elimination
- Hemodialysis within 4-6 hours (limited efficacy but may remove some paraquat)
- Charcoal hemoperfusion if available
- Continuous venovenous hemofiltration

Antioxidant Therapy

Evidence-based approaches:

N-acetylcysteine: 140 mg/kg loading, then 70 mg/kg q4h
High-dose methylprednisolone: 1g daily x 3 days, then taper
Cyclophosphamide: 15 mg/kg daily (in combination protocols)

Experimental therapies:

Superoxide dismutase mimetics: Tempol, MnTBAP
Vitamin E and selenium: High-dose supplementation

Critical Care Management

🔍 Clinical Pearl: Avoid supplemental oxygen unless PaO2 <60 mmHg. Hyperoxia accelerates paraquat-induced lung injury through enhanced free radical formation¹⁵.

Respiratory Management
- Target SpO2 85-88% to minimize oxygen toxicity
- PEEP strategy to maintain recruitment
- Consider prone positioning for ARDS
- Lung-protective ventilation strategies
Renal Support
- Early RRT for volume overload or uremia
- CRRT preferred over intermittent HD
- Monitor for compartment syndrome from fluid overload
Cardiovascular Support
- Continuous cardiac monitoring
- Vasopressor support as needed
- Echocardiography to assess myocardial function

💡 Management Pearl: The "paraquat protocol" combines immunosuppression (methylprednisolone + cyclophosphamide) with antioxidants (NAC + selenium). While controversial, some centers report improved survival in moderate poisoning cases¹⁶.

Comparative ICU Management Strategies

Toxidrome	Primary Antidote	Key Monitoring	Prognosis Indicators
Bupropion	Sodium bicarbonate	QRS duration, seizures	QRS >120ms = poor
Synthetic Cannabinoids	None	Potassium, coags	Severe hypokalemia = poor
Paraquat	Antioxidants + immunosuppression	PaO2/FiO2, creatinine	>6 mg/kg ingested = poor

Clinical Decision-Making Algorithms

Bupropion Toxicity Algorithm

Suspected Bupropion Overdose
↓
Obtain ECG + Labs
↓
QRS >100ms OR Seizures?
├─ Yes → Sodium bicarbonate + Seizure control
└─ No → Supportive care + Monitor q2h ECG
↓
Refractory seizures?
├─ Yes → Propofol/Barbiturates + Consider lipid emulsion
└─ No → Continue monitoring 24+ hours

Paraquat Poisoning Algorithm

Suspected Paraquat Exposure
↓
<4 hours since ingestion?
├─ Yes → Fuller's earth/Charcoal + Hemodialysis
└─ No → Supportive care only
↓
Calculate severity (mg/kg ingested)
├─ >40 mg/kg → Palliative care discussion
├─ 20-40 mg/kg → Aggressive antioxidant protocol
└─ <20 mg/kg → Standard antioxidant therapy
↓
Avoid oxygen unless PaO2 <60 mmHg

Prognostic Factors and Outcomes

Bupropion Toxicity

Good prognosis: QRS <100ms, no seizures within 8 hours
Poor prognosis: Status epilepticus, QRS >120ms, metabolic acidosis
Mortality: <5% with appropriate management²

Synthetic Cannabinoids

Variable outcomes: Depends on specific compound and adulterants
Good prognosis: Isolated CNS symptoms
Poor prognosis: Cardiovascular collapse, severe hypokalemia, coagulopathy
Mortality: 1-3% overall, higher with adulterants⁸

Paraquat Poisoning

Uniformly poor: >90% mortality with moderate-severe ingestions
Survival factors: Early presentation, minimal ingestion, aggressive early treatment
Mortality: 60-90% overall¹²

Future Directions and Research

Emerging Therapies

Lipid emulsion therapy: Expanding evidence for lipophilic toxins
ECMO protocols: Standardized approaches for cardiotoxic poisonings
Molecular adsorbents: Novel extracorporeal detoxification methods
Targeted antioxidants: Mitochondria-specific compounds for paraquat

Diagnostic Advances

Point-of-care testing: Rapid synthetic cannabinoid detection
Metabolomics: Pattern recognition for unknown toxidromes
AI-assisted diagnosis: Machine learning for toxidrome recognition

Clinical Pearls Summary

🔍 Diagnostic Pearls

Bupropion: QRS >100ms predicts seizure risk better than drug levels
Synthetic Cannabinoids: Severe hypokalemia with negative drug screen is pathognomonic
Paraquat: Calculate severity index (mg/kg) immediately upon presentation

⚠️ Critical Oysters

Bupropion: Extended-release formulations cause delayed toxicity up to 24 hours
Synthetic Cannabinoids: Standard drug screens are falsely negative
Paraquat: Asymptomatic latent period precedes severe toxicity

🔧 ICU Hacks

Bupropion: Continuous ECG monitoring more valuable than intermittent checks
Synthetic Cannabinoids: Require massive potassium replacement (often >200 mEq)
Paraquat: Avoid oxygen supplementation unless PaO2 <60 mmHg

💡 Management Pearls

Bupropion: Lipid emulsion therapy for refractory cases
Synthetic Cannabinoids: Consider brodifacoum coagulopathy with prolonged PT
Paraquat: Combined immunosuppression + antioxidant protocols may help moderate cases

Conclusion

Rare ICU toxidromes demand a systematic approach combining pattern recognition, aggressive supportive care, and toxin-specific interventions. While outcomes vary significantly among these three syndromes, early recognition and appropriate management can dramatically impact patient survival and morbidity.

The key to mastery lies in understanding the unique pathophysiology of each toxidrome, recognizing their characteristic presentations, and implementing evidence-based treatment protocols promptly. As new synthetic compounds emerge and exposure patterns evolve, critical care physicians must remain vigilant and adaptable in their approach to these challenging cases.

Future research should focus on developing targeted antidotes, improving early detection methods, and establishing standardized treatment protocols for these rare but potentially lethal poisonings.

References

Stahl SM, Pradko JF, Haight BR, et al. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166.
Starr P, Klein-Schwartz W, Spiller H, et al. Incidence and onset of delayed seizures after bupropion overdoses. Am J Emerg Med. 2009;27(8):911-915.
Cooper J, Kirkpatrick P. Bupropion. Nat Rev Drug Discov. 2005;4(2):97-98.
Balit CR, Lynch CN, Isbister GK. Bupropion poisoning: a case series. Med J Aust. 2003;178(2):61-63.
Jamaty C, Bailey B, Larocque A, et al. Lipid emulsions in the treatment of acute poisoning: a systematic review of human and animal studies. Clin Toxicol. 2010;48(1):1-27.
Auwärter V, Dresen S, Weinmann W, et al. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009;44(5):832-837.
Hoyte CO, Jacob J, Monte AA, et al. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012;60(4):435-438.
Law R, Schier J, Martin C, et al. Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use - United States, January-May 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):618-619.
Sherpa D, Paudel BM, Subedi BK, et al. Synthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high. Case Rep Crit Care. 2015;2015:324585.
Adams AJ, Banister SD, Irizarry L, et al. "Zombie" outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med. 2017;376(3):235-242.
Dinis-Oliveira RJ, Duarte JA, Sánchez-Navarro A, et al. Paraquat poisonings: mechanisms of lung toxicity, clinical features, and treatment. Crit Rev Toxicol. 2008;38(1):13-71.
Proudfoot AT, Stewart MS, Levitt T, Widdop B. Paraquat poisoning: significance of plasma-paraquat concentrations. Lancet. 1979;2(8138):330-332.
Senarathna L, Eddleston M, Wilks MF, et al. Prediction of outcome after paraquat poisoning by measurement of the plasma paraquat concentration. QJM. 2009;102(4):251-259.
Hart TB, Nevitt A, Whitehead A. A new statistical approach to the prognostic significance of plasma paraquat concentrations. Lancet. 1984;2(8413):1222-1223.
Smith P, Heath D. Paraquat. CRC Crit Rev Toxicol. 1976;4(4):411-445.
Lin JL, Leu ML, Liu YC, Chen GH. A prospective clinical trial of pulse therapy with glucocorticoid and cyclophosphamide in moderate to severe paraquat-poisoned patients. Am J Respir Crit Care Med. 1999;159(2):357-360.

Sunday, September 21, 2025